DiaSorin unit Luminex in pact with Cytek to sell FCI assets, no terms

DiaSorin and Cytek Biosciences announced that Luminex , a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging FCI business unit. The sale is expected to close within 30 days, subject to customary closing conditions. The FCI business unit, acquired by Luminex in October 2018, is based on both conventional flow cytometry and image-based flow cytometry instrumentation, which provide insights into all facets of cellular phenotypes and morphology. The FCI business unit includes dedicated commercial, operations, R&D, and supporting personnel. An existing installed base of more than 7,000 instruments will be under the Cytek umbrella following the acquisition, expanding the company’s global commercial footprint.The decision to sell the FCI business unit to Cytek is in line with the strategic priorities communicated to investors during the Capital Market Day in December 2021."We are currently working on several projects that will allow DiaSorin to further growth and strengthen our positioning as a specialty player over the next years," commented Angelo Rago, president of Luminex. "To do so, we need to be extremely focused on the core for our future and, therefore, we decided to sell the Flow Cytometry & Imaging business unit to a dedicated, leading player in the space. We are convinced that Cytek will be able to grow it with success in the future."